Oncotarget From Wikipedia

Oncotarget

From Wikipedia, the free encyclopedia
Jump to navigationJump to search
Oncotarget  
LanguageEnglish
Edited byMikhail Blagosklonny, Andrei V. Gudkov
Publication details
History2010-present
Publisher
FrequencyWeekly
Yes
LicenseCreative Commons Attribution 3.0 License
Standard abbreviations
ISO 4Oncotarget
Indexing
ISSN1949-2553
OCLC no.408119940
Links

Oncotarget is a twice weekly peer-reviewed open access bio-medical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology. The journal was established in 2010 and is published by Impact Journals. The editors-in-chief are Mikhail Blagosklonny and Andrei V. Gudkov.

In 2017, the journal was dropped from MEDLINE.[1][2] In 2018 Clarivate Analytics, who maintain the most prominent Impact factor index, delisted the journal from the Journal Citation Reports and all of its other products because "the journal no longer meets the standards necessary for continued coverage",[3] despite having listed the journal as a "Rising Star from Essential Science Indicators"[4] only a few months prior.[5]

Abstracting and indexing[edit]

The journal is abstracted and indexed in PubMed[6], Meta,[7][8][9] and Scopus.[10] It was dropped from Index Medicus/MEDLINE[1][2][6] in 2017 and in 2018 from BIOSIS Previews and the Science Citation Index Expanded.[3]

Reception[edit]

The peer review process employed by the journal has been criticized by Jeffrey Beall,[11] a university librarian and expert on predatory open access publishing, who also included the journal on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015.[11][12] Allegedly, journal editor Mikhail Blagosklonny responded by threatening to retract the papers of Beall's colleagues at the University of Colorado.[1][2]


References[edit]

  1. ^ Jump up to:a b c "Widely used U.S. government database delists cancer journal". Retraction Watch. October 25, 2017. Retrieved October 25, 2017.
  2. ^ Jump up to:a b c Zimmer, Katarina (October 26, 2017). "Oncotarget Journal Cut from Medline". The Scientist.
  3. ^ Jump up to:a b "Indexing company praises cancer journal, then kicks it out". Retraction Watch. 2018-01-19. Retrieved 2018-01-20.
  4. ^ "Rising Stars from Essential Science Indicators". Clarivate Analytics. 2017-10-18. Retrieved 2018-01-21.
  5. ^ "Indexing company praises cancer journal, then kicks it out". Retraction Watch. 2018-01-19. Retrieved 2018-01-21.
  6. ^ Jump up to:a b "Oncotarget". NLM Catalog. National Center for Biotechnology Information. Retrieved 2016-04-19.
  7. ^ "Oncotarget | In The News - Press Releases". Retrieved 2018-03-15.
  8. ^ "When a journal is delisted, authors pay a price". Retraction Watch. 2018-03-06. Retrieved 2018-03-15.
  9. ^ Oncotarget. "Oncotarget to be Indexed in Highly Esteemed Meta Database". www.prnewswire.com. Retrieved 2018-03-15.
  10. ^ "Source details: Oncotarget". Scopus preview. Elsevier. Retrieved 2018-01-27.
  11. ^ Jump up to:a b Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. WordPress.com. Archived from the original on 20 April 2016. Retrieved 19 April2016.
    "Oncotarget's Peer Review is Highly Questionable (Jeffrey Beall". KSCIEN (Reprint of Beall's blog post). Retrieved 27 Dec2019.
  12. ^ Beall, Jeffrey (16 April 2016). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. WordPress.com. Archived from the original on 2 December 2016. Retrieved 19 April 2016.

External links[edit]


When people discuss today’s medicine, accuracy plays one of the most important roles and people’s lives are literally dependent on it. Likewise, any researches pertaining to medicine are required to comply with the highest standards. The challenge nowadays is that any conclusions of researches can be posted online and used as a reference without being properly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The major principle of this journal is based on Altmetric scores that are used as a quality indicator. That assists both readers and authors to validate publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a full publications list with corresponding scores above 100 as well as reports discussed above. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it provides the required assistance to anyone, who has interest in oncology.
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This paper was released back in 2018 by Oncotarget and completed by diversified experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study discusses “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are aiming to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hereby, the paper about melanoma, was utilized for citations in various news articles 69 times. Besides that, it was referred to in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study 
Another Oncotarget’s study with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a short overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive helpful scientific facts. Oncotarget is happy to have the ability to share with online viewers this highly appreciated and high-quality information, that is trustworthy and reliable.

Comments

  1. AnonymousDecember 22, 2022 at 10:26 PM

    Hey thanks for sharing this amazing content, We also have some amazing content to reduce workplace stress at Resiliency Program

    ReplyDelete
  2. AnonymousDecember 22, 2022 at 10:28 PM

    Het artikel is echt geweldig, bedankt! Kun je ook iets schrijven over software ontwikkelaar?

    ReplyDelete

Post a Comment

Popular posts from this blog

Validation of anti-aging drugs by treating age-related diseases

Validation of anti-aging drugs by treating age-related diseases Mikhail V. Blagosklonny 1 1  Cancer Center, Ordway Research Institute, Albany, NY 12208, USA Received: September 20, 2008          Accepted: March 28, 2009          Published: March 28, 2009 https://doi.org/10.18632/aging.100034 How to Cite Abstract Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical
Read more

Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma

Image
Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma ABSTRACT Background:  Glioblastoma (GBM) confers a dismal prognosis despite advances in current therapy. Cancer-testis antigens (CTA) comprise families of tumor-associated antigens that are immunogenic in different cancers. The aim of this study was to determine the expression profile of a large number of CTA genes in GBM. Methods:  We selected, from 153 CTA genes, those genes potentially expressed in GBM. The expression pattern of 30 CTA was then evaluated by RT-PCR in a series of 48 GBM and 5 normal brain samples. The presence of CTCFL protein was also evaluated by immunohistochemical staining. Results:  Among the genes with no expression in normal brain, ACTL8 (57%), OIP5 (54%), XAGE3 (44%) and CTCFL (15%) were frequently expressed in GBM, while over 85% of the tumors expressed at least 1 of these four CTA. Coexpression of two or more CTA occurred in 49% of cases. CTCFL protein expression was d
Read more

Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin

Image
Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin Olga V. Leontieva, Zoya N. Demidenko, Andrei V. Gudkov, Mikhail V. Blagosklonny Abstract Background Depending on cellular context, p53-inducing agents (such as nutlin-3a) cause different outcomes including reversible quiescence and irreversible senescence. Inhibition of mTOR shifts the balance from senescence to quiescence. In cell lines with incomplete responses to p53, this shift may be difficult to document because of a high proportion of proliferating cells contaminating arrested (quiescent and senescent) cells. This problem also complicates the study of senescence caused by minimal levels of p21 that are capable to arrest a few cells. Methodology During induction of senescence by low levels of endogenous p53 and ectopic p21, cells were co-treated with nocodazole, which eliminated proliferating cells. As a result, only senescent and quiescent cells remained. Results and Discussion
Read more

A novel DNA damage response mediated by DNA mismatch repair in Caenorhabditis elegans: induction of programmed autophagic cell death in non-dividing cells

A novel DNA damage response mediated by DNA mismatch repair in  Caenorhabditis elegans : induction of programmed autophagic cell death in non-dividing cells https://player.fm/podcasts/open-access ABSTRACT DNA mismatch repair (MMR) contributes to genome integrity by correcting errors of DNA polymerase and inducing cell death in response to DNA damage. Dysfunction of MMR results in increased mutation frequency and cancer risk. Clinical researches revealed that MMR abnormalities induce cancers of non-dividing tissues, such as kidney and liver. However, how MMR suppresses cancer in non-dividing tissues is not understood. To address that mechanism, we analyzed the roles of MMR in non-dividing cells using  Caenorhabditis elegans  ( C. elegans ), in which all somatic cells are non-dividing in the adult stage. In this study, we used stable MMR-mutant lines with a balancer chromosome. First, we confirmed that deficiency of MMR leads to resistance to various mutagens in  C. elegans  dividing cel
Read more

The story behind Oncotarget

The story behind Oncotarget? A bibliometric analysis Abstract Being the most proliferative journal of oncology a cancer research of the past decade, the Open Access journal Oncotarget had reached more than 20,000 publications and a relatively high impact factor score in the past years. In 2018, the journal citation report decided to withdraw the status of an impact factor journal. Since there was a large discussion in the scientific community and specific reasons for the withdrawal were not stated, this bibliometric analysis was performed to assess if Oncotarget exhibits any differences in its bibliometric structure compared to other journals. For this purpose, we used the “New Quality and Quantity Indices in Sciences” platform and analyzed 20,000 Oncotarget articles. Density equalizing mapping technique helps to construct maps of cancer research in Oncotarget and shows that it has led to a unique global landscape which is not asymmetrically dominated by the Western hemisphere but exhi
Read more

Aging: Cancer – an unlikely couple

Image
Aging: Cancer – an unlikely couple     https://www.aging-us.com/issue/v9i9 At first glance, the molecular and cellular mechanisms governing aging and cancer appear to be completely distinct, even opposite in terms of their phenotypes. On one hand, aging represents a slow, often degenerative decline in cellular functions, while cancer cells are thought be “hyper-functional”. But are they really that opposite? It is no secret that aging increases one’s susceptibility to many diseases, including cancer. In fact, as aging populations throughout the world increase, there has been an unprecedented rise in cancer incidence and mortality. More than 50 percent of all cancers are diagnosed in patients 65 years or older [1]. There is now more than ever an urgent need to better understand the interplay between aging and cancer. This knowledge will undoubtedly improve clinical management of geriatric cancer patients. Here, we discuss some intriguing factors linking these two seemingly paradoxical c
Read more

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers ABSTRACT This study evaluated the effects of a modern antagonistic analog of GHRH on tumor growth and on expression of inflammatory cytokine genes in two models of human triple negative breast cancers (TNBC). The TNBC subtype is refractory to the treatment options available for other hormone-independent breast cancers. Inflammatory cytokines play a major role in the cellular signaling associated with breast cancer pathogenesis and enhance epithelial-mesenchymal transitions (EMT), drug resistance, and metastatic potential. Growth hormone-releasing hormone (GHRH) is a hypothalamic neuropeptide which regulates the synthesis and release of growth hormone by the pituitary and is an autocrine/paracrine growth factor for multiple human cancers. The effects of analogs of GHRH on tumoral cytokine expression have not been previously investigated. Animals bearing xen
Read more

Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity

Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity ABSTRACT The neuropilins (Nrps) are multifunctional proteins involved in development, immunity and cancer. Neuropilin-1 (Nrp1), or its homologue neuropilin-2 (Nrp2), are coreceptors that enhance responses to several growth factors (GFs) and other mediators. Nrps are coreceptors for the class 3 semaphorins (SEMA3), involved in axonal guidance, and several members of the vascular endothelial growth factor (VEGF) family. However, recent findings reveal they have a much broader spectrum of activity. They bind transforming growth factor β1 (TGF-β1) and its receptors, hepatocyte growth factor (HGF) and its receptor (cMet), platelet derived growth factor (PDGF) and its receptors, fibroblast growth factors (FGFs), and integrins. Nrps also promote Hedgehog signaling. These ligands and pathways are all relevant to angiogenesis and wound healing. In the immune system, the Nrps are expressed p
Read more

To Oncotarget or not to Oncotarget

To Oncotarget or not to Oncotarget Starting from January 2018, Oncotarget is no longer listed in SCIE (Science Citation Index Expanded). This is shocking news to a lot of scientists because the journal was deemed a “rising star” in the field of molecular biology & genetics just a short three months ago by Clarivate Analytics (see the blog post here), the very company that delisted Oncotarget from their journal index products. To some people, it may not be completely surprising because earlier Oncotarget was dropped from MEDLINE, the journal index database of the US National Library of Medicine (NLM). Neither MEDLINE nor Clarivate Analytics gave specific reasons of removing Oncotarget from their indexes. Interested readers can find MEDLINE’s guidelines for deselecting journals here, and Clarivate Analytics’ criteria for indexing journals in their lists here. For a brief period after Oncotarget was removed from MEDLINE, new articles published in the journal could not be searched in P
Read more